Key clinical point: Reduced intensity conditioning (RIC) transplant in first remission vs. chemotherapy alone improved survival in older patients with acute myeloid leukemia (AML) who lacked favorable risk cytogenetics and were considered fit for intensive treatment.
Major finding: During a median follow-up of 60 months from remission, patients receiving RIC transplant vs. no transplant had superior survival (37% vs. 20%; hazard ratio [HR] 0.67; P < .001). Survival benefit with transplant in first remission vs. chemotherapy alone was observed across all Wheatley risk groups (adjusted HR 0.68; P < .001).
Study details: Findings are from the NCRI AML16 trial including 932 patients (age 60-70 years) with AML who entered remission and lacked favorable risk. Of these, 144 underwent RIC transplants from either matched sibling donors (n = 52) or matched unrelated donors (n = 92).
Disclosures: This NCRI AML16 trial was supported by Cancer Research UK. The authors declared no conflict of interests.
Source: Russell NH et al. Haematologica. 2021(Oct 14). Doi: 10.3324/haematol.2021.279010.